Feng JF - Search Results

1

Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.

Sha HH, Wang DD, Yan DL, Hu Y, Yang SJ, Liu SW, Feng JF. Sha HH, et al. Among authors: feng jf. Biosci Rep. 2017 Jan 27;37(1):BSR20160332. doi: 10.1042/BSR20160332. Print 2017 Feb 28. Biosci Rep. 2017. PMID: 28053197 Free PMC article. Review.

2

Antiangiogenic therapy in the management of breast cancer.

Wu Y, Sun WL, Feng JF. Wu Y, et al. Among authors: feng jf. Asia Pac J Clin Oncol. 2013 Jun;9(2):110-6. doi: 10.1111/j.1743-7563.2012.01569.x. Epub 2012 Jul 9. Asia Pac J Clin Oncol. 2013. PMID: 22898270 Review.

3

Comparison of nedaplatin-based versus cisplatin-based chemotherapy for advanced non-small cell lung cancer among East Asian populations: A meta-analysis.

Liu Y, Yu S, Liu S, Cao H, Ma R, Wu J, Feng J. Liu Y, et al. Sci Rep. 2015 May 21;5:10516. doi: 10.1038/srep10516. Sci Rep. 2015. PMID: 25994814 Free PMC article.

4

[Analysis of C.3925_3929 deletional mutations of APC gene in pedigrees with familial adenomatous polyposis].

Chen Q, Liu S, Feng J, Zhang X, Chen S, Ma G, Zhu M, Zhang Y, Yu J. Chen Q, et al. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2015 Aug;32(4):524-8. doi: 10.3760/cma.j.issn.1003-9406.2015.04.017. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2015. PMID: 26252100 Chinese.

5

LXR ligands sensitize EGFR-TKI-resistant human lung cancer cells in vitro by inhibiting Akt activation.

Wu Y, Yu DD, Hu Y, Cao HX, Yu SR, Liu SW, Feng JF. Wu Y, et al. Among authors: feng jf. Biochem Biophys Res Commun. 2015 Nov 27;467(4):900-5. doi: 10.1016/j.bbrc.2015.10.047. Epub 2015 Oct 21. Biochem Biophys Res Commun. 2015. PMID: 26471306

6

WITHDRAWN: The long non-coding RNA, LINC00635-001, sensitizes EGFR-TKI-resistant human lung cancer cells in vitro by inhibiting Akt activation.

Wu Y, Yu DD, Hu Y, Yan DL, Chen X, Zhang HD, Cao HX, Yu SR, Wang Z, Feng JF. Wu Y, et al. Among authors: feng jf. Biochem Biophys Res Commun. 2016 Jan 11:S0006-291X(16)30057-2. doi: 10.1016/j.bbrc.2016.01.057. Online ahead of print. Biochem Biophys Res Commun. 2016. PMID: 26792719

7

Liver X receptor as a drug target for the treatment of breast cancer.

Wu Y, Yu DD, Yan DL, Hu Y, Chen D, Liu Y, Zhang HD, Yu SR, Cao HX, Feng JF. Wu Y, et al. Among authors: feng jf. Anticancer Drugs. 2016 Jun;27(5):373-82. doi: 10.1097/CAD.0000000000000348. Anticancer Drugs. 2016. PMID: 26872310 Review.

8

Genome-wide profiling of long non-coding RNA expression patterns in the EGFR-TKI resistance of lung adenocarcinoma by microarray.

Wu Y, Yu DD, Hu Y, Yan D, Chen X, Cao HX, Yu SR, Wang Z, Feng JF. Wu Y, et al. Among authors: feng jf. Oncol Rep. 2016 Jun;35(6):3371-86. doi: 10.3892/or.2016.4758. Epub 2016 Apr 20. Oncol Rep. 2016. PMID: 27108960

9

Reversal effects of local anesthetics on P-glycoprotein-mediated cancer multidrug resistance.

Hu Y, Qin X, Cao H, Yu S, Feng J. Hu Y, et al. Anticancer Drugs. 2017 Mar;28(3):243-249. doi: 10.1097/CAD.0000000000000455. Anticancer Drugs. 2017. PMID: 27906699 Review.

10

Liver X receptor agonist T0901317 reverses resistance of A549 human lung cancer cells to EGFR-TKI treatment.

Cao H, Yu S, Chen D, Jing C, Wang Z, Ma R, Liu S, Ni J, Feng J, Wu J. Cao H, et al. FEBS Open Bio. 2016 Dec 20;7(1):35-43. doi: 10.1002/2211-5463.12147. eCollection 2017 Jan. FEBS Open Bio. 2016. PMID: 28097086 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

490 results

Search Page